119 related articles for article (PubMed ID: 20646838)
1. Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions.
He X; Wei Q; Zhang X; Xiao J; Jin X; Zhu Y; Cui B; Ning G
Pathol Res Pract; 2010 Oct; 206(10):712-5. PubMed ID: 20646838
[TBL] [Abstract][Full Text] [Related]
2. Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues.
Johnson TL; Lloyd RV; Thor A
Am J Pathol; 1987 Apr; 127(1):60-5. PubMed ID: 3105323
[TBL] [Abstract][Full Text] [Related]
3. c-Met expression in tall cell variant papillary carcinoma of the thyroid.
Nardone HC; Ziober AF; LiVolsi VA; Mandel SJ; Baloch ZW; Weber RS; Mick R; Ziober BL
Cancer; 2003 Oct; 98(7):1386-93. PubMed ID: 14508824
[TBL] [Abstract][Full Text] [Related]
4. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307
[TBL] [Abstract][Full Text] [Related]
5. Retinoblastoma expression in thyroid neoplasms.
Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemistry of the thyroid in surgical and cytologic specimens.
Davila RM; Bedrossian CW; Silverberg AB
Arch Pathol Lab Med; 1988 Jan; 112(1):51-6. PubMed ID: 3337618
[TBL] [Abstract][Full Text] [Related]
7. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
8. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
9. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.
Fernández PL; Merino MJ; Gómez M; Campo E; Medina T; Castronovo V; Sanjuán X; Cardesa A; Liu FT; Sobel ME
J Pathol; 1997 Jan; 181(1):80-6. PubMed ID: 9072007
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic contribution of HBME-1 and anti-cytokeratin-19 antibodies in thyroid pathology: a retrospective study of 163 cases].
Ziadi S; Trimeche M; Zermani R; Elmay A; Baltagi-Ben Jilani S
Tunis Med; 2005 May; 83(5):274-8. PubMed ID: 16044900
[TBL] [Abstract][Full Text] [Related]
11. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
12. [Poorly differentiated carcinoma of the thyroid--immunohistochemical evaluation of p53 and p27 protein expression].
Wierzchowski W; Szybiński P; Nowak W; Nowak K; Szybiński Z; Buziak-Bereza M; Stachura J
Wiad Lek; 2001; 54 Suppl 1():79-87. PubMed ID: 12182066
[TBL] [Abstract][Full Text] [Related]
13. [HBME-1 immunostaining in thyroid pathology].
Rigau V; Martel B; Evrard C; Rousselot P; Galateau-Salle F
Ann Pathol; 2001 Feb; 21(1):15-20. PubMed ID: 11223556
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis.
Cornetta AJ; Russell JP; Cunnane M; Keane WM; Rothstein JL
Laryngoscope; 2002 Feb; 112(2):238-42. PubMed ID: 11889377
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
16. Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases.
Bradly DP; Reddy V; Prinz RA; Gattuso P
Surgery; 2009 Dec; 146(6):1099-104. PubMed ID: 19958937
[TBL] [Abstract][Full Text] [Related]
17. Expression of D2-40 in adjunct diagnosis of papillary thyroid carcinoma.
Wang SL; Li SH; Chen WT; Chai CY
APMIS; 2007 Aug; 115(8):906-10. PubMed ID: 17696946
[TBL] [Abstract][Full Text] [Related]
18. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
